FORTITUDE-HCM is a global, multicenter, double-blind, parallel-group, placebo-controlled Phase 2b study that will assess the efficacy and safety of ninerafaxstat compared to placebo on top of Standard of Care in patients with symptomatic nHCM

Select Inclusion Criteria:

• Has a clinical diagnosis of HCM consistent with current American College of Cardiology/American Heart Association and European Society of Cardiology Guideline definitions
• Has had confirmation of nHCM by the echocardiography core laboratory based on screening rest and exercise stress echocardiography
• New York Heart Association (NYHA) functional Class II or III at screening
• Functional limitation as defined by a screening CPET

Select Exclusion Criteria:

• Has a known or suspected infiltrative, genetic, or storage disorder causing cardiac hypertrophy that mimics nHCM
• Has any other condition judged by the investigator to be the primary cause of dyspnea, exercise intolerance, and/or angina
• Has an inability to exercise on a treadmill or bicycle (eg, orthopedic limitations)
• Has any medical condition that precludes upright exercise stress testing

Other protocol-defined inclusion and exclusion criteria apply.